drugset / Trial / NCT01146327
A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects
RandomizedParallel-groupTriple-blindTreatment
Summary
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, and pharmacodynamics, of multiple oral doses of PF-04620110.
Timeline
- Start
- 2010-06
- Primary completion
- 2011-01
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-04620110 | Small molecule | 1.5 mg | Oral |
| Subject | PF-04620110 | Small molecule | 2.5 mg | Oral |
| Subject | PF-04620110 | Small molecule | 3 mg | Oral |
| Subject | PF-04620110 | Small molecule | 5 mg | Oral |
Indications
No indication recorded.